Wrightington Hosptial
Welcome,         Profile    Billing    Logout  
 0 Trials 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gregory, Christopher
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24

Download Options